RxDoctor Payments Data

Bhalchandra Parulkar, MD

Urology · Worcester, MANPI 1164531422

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $23,993 of the $39,350 with a category attached, or 61.0%. 43 manufacturers reported payments, led by Covidien LP at 33.5% of the total. Reporting peaked in 2020 at $14,487 and has fallen 80.2% since, to $2,874 in 2025. Among urology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,350in general payments, 2019–2025

Across 363 payments — averaging $108.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$13K
  • Medtronic$8K
  • Ambu A/s$2K
  • Davol Inc.$2K
  • Coloplast$1K
  • Boston Scientific$1K
  • plus $11K from 37 others

What the payments were for

  • Consulting fees$23,99361%
  • Speaking & faculty fees$3,5509%
  • Travel & lodging$1,0753%
  • Food & beverage$10,56127%
  • Education$1710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,350 in reported general payments places this provider in the 90th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$296,297
Medicare patients
739
Services billed
4,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron73$59,916
OrgovyxRelugolix13$34,453
Tamsulosin Hcl993$20,468
Finasteride940$16,035
Solifenacin Succinate31$3,029
Oxybutynin Chloride ErOxybutynin Chloride91$2,803
Dutasteride54$1,943
Tolterodine Tartrate ErTolterodine Tartrate22$1,851
Alfuzosin Hcl ErAlfuzosin Hcl70$1,733
Silodosin16$1,580
Potassium Citrate ErPotassium Citrate12$1,501
Terazosin Hcl40$684
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$494
Doxazosin Mesylate19$467
NitrofurantoinNitrofurantoin Macrocrystal20$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$879$59,91673 claims
Sumitomo Pharma America, Inc.Orgovyx$99$34,45313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 327 urology providers in Massachusetts.

Other urology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →